View in EDS HTML Full Text PDF Full Text

Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.

Saved in:
Bibliographic Details
Title: Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Authors: Gil‐López, F. J., Montoya, J., Falip, M., Aparicio, J., López‐González, F. J., Toledano, R., Gil‐Nagel, A., Molins, A., García, I., Serrano, P., Domenech, G., Torres, F., Donaire, A., Carreño, M.
Source: Acta Neurologica Scandinavica. Aug2018, Vol. 138 Issue 2, p122-129. 8p.
Subjects: Anticonvulsants, Partial epilepsy, Myoclonus, Dizziness, Acquisition of data, Therapeutics
Abstract: Objectives: Perampanel is an antiepileptic drug (AED) approved for add‐on treatment of focal seizures (with or without generalization) and primary generalized tonic‐clonic (GTC) seizures. Our objective was to explore the effectiveness and tolerability of adjunctive perampanel in patients with drug‐resistant myoclonic seizures, after failure of other AEDs. Materials and methods: Retrospective, multicenter, observational study. Data were collected from individual patient clinical files and analysed using appropriate descriptive statistics and inferential analyses. Results: Data are reported for 31 patients with mean age 36.4 years, who had an average epilepsy duration of 18 years, previously taken an average of 5.03 AEDs, and were taking an average of 2.4 AEDs on perampanel initiation. Patients exhibited myoclonic, GTC, absence, tonic and focal seizures, and most had associated cognitive decline and/or ataxia. Median time on perampanel was 6 months, most common dose was 6 mg, and overall retention rate was 84%. The responder rate for myoclonic seizures was defined via reduction of days with myoclonic seizures per month. At 6 months, 15 (48.4%) of the 31 patients were classed as myoclonic seizure responders, 10 (32.3%) were myoclonic seizure free, and 39% saw improvements in functional ability. Of 17 patients with GTC seizures at baseline, 9 (53%) were responders at 6 months, and 8 (47.1%) were seizure free. The most frequent side effects were psychiatric disorders, instability, dizziness and irritability, and mostly resolved with dose reduction. Five patients discontinued perampanel due to side effects. Conclusions: Perampanel caused clinically meaningful improvements in patients with drug‐resistant myoclonic seizures. It was generally well tolerated, but psychiatric and neurological side effects sometimes required follow‐up and dose reduction. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 130547835
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Gil‐López%2C+F%2E+J%2E%22">Gil‐López, F. J.</searchLink><br /><searchLink fieldCode="AR" term="%22Montoya%2C+J%2E%22">Montoya, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Falip%2C+M%2E%22">Falip, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Aparicio%2C+J%2E%22">Aparicio, J.</searchLink><br /><searchLink fieldCode="AR" term="%22López‐González%2C+F%2E+J%2E%22">López‐González, F. J.</searchLink><br /><searchLink fieldCode="AR" term="%22Toledano%2C+R%2E%22">Toledano, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Gil‐Nagel%2C+A%2E%22">Gil‐Nagel, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Molins%2C+A%2E%22">Molins, A.</searchLink><br /><searchLink fieldCode="AR" term="%22García%2C+I%2E%22">García, I.</searchLink><br /><searchLink fieldCode="AR" term="%22Serrano%2C+P%2E%22">Serrano, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Domenech%2C+G%2E%22">Domenech, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Torres%2C+F%2E%22">Torres, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Donaire%2C+A%2E%22">Donaire, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Carreño%2C+M%2E%22">Carreño, M.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Aug2018, Vol. 138 Issue 2, p122-129. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Anticonvulsants%22">Anticonvulsants</searchLink><br /><searchLink fieldCode="DE" term="%22Partial+epilepsy%22">Partial epilepsy</searchLink><br /><searchLink fieldCode="DE" term="%22Myoclonus%22">Myoclonus</searchLink><br /><searchLink fieldCode="DE" term="%22Dizziness%22">Dizziness</searchLink><br /><searchLink fieldCode="DE" term="%22Acquisition+of+data%22">Acquisition of data</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objectives: Perampanel is an antiepileptic drug (AED) approved for add‐on treatment of focal seizures (with or without generalization) and primary generalized tonic‐clonic (GTC) seizures. Our objective was to explore the effectiveness and tolerability of adjunctive perampanel in patients with drug‐resistant myoclonic seizures, after failure of other AEDs. Materials and methods: Retrospective, multicenter, observational study. Data were collected from individual patient clinical files and analysed using appropriate descriptive statistics and inferential analyses. Results: Data are reported for 31 patients with mean age 36.4 years, who had an average epilepsy duration of 18 years, previously taken an average of 5.03 AEDs, and were taking an average of 2.4 AEDs on perampanel initiation. Patients exhibited myoclonic, GTC, absence, tonic and focal seizures, and most had associated cognitive decline and/or ataxia. Median time on perampanel was 6 months, most common dose was 6 mg, and overall retention rate was 84%. The responder rate for myoclonic seizures was defined via reduction of days with myoclonic seizures per month. At 6 months, 15 (48.4%) of the 31 patients were classed as myoclonic seizure responders, 10 (32.3%) were myoclonic seizure free, and 39% saw improvements in functional ability. Of 17 patients with GTC seizures at baseline, 9 (53%) were responders at 6 months, and 8 (47.1%) were seizure free. The most frequent side effects were psychiatric disorders, instability, dizziness and irritability, and mostly resolved with dose reduction. Five patients discontinued perampanel due to side effects. Conclusions: Perampanel caused clinically meaningful improvements in patients with drug‐resistant myoclonic seizures. It was generally well tolerated, but psychiatric and neurological side effects sometimes required follow‐up and dose reduction. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=130547835
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ane.12931
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 122
    Subjects:
      – SubjectFull: Anticonvulsants
        Type: general
      – SubjectFull: Partial epilepsy
        Type: general
      – SubjectFull: Myoclonus
        Type: general
      – SubjectFull: Dizziness
        Type: general
      – SubjectFull: Acquisition of data
        Type: general
      – SubjectFull: Therapeutics
        Type: general
    Titles:
      – TitleFull: Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gil‐López, F. J.
      – PersonEntity:
          Name:
            NameFull: Montoya, J.
      – PersonEntity:
          Name:
            NameFull: Falip, M.
      – PersonEntity:
          Name:
            NameFull: Aparicio, J.
      – PersonEntity:
          Name:
            NameFull: López‐González, F. J.
      – PersonEntity:
          Name:
            NameFull: Toledano, R.
      – PersonEntity:
          Name:
            NameFull: Gil‐Nagel, A.
      – PersonEntity:
          Name:
            NameFull: Molins, A.
      – PersonEntity:
          Name:
            NameFull: García, I.
      – PersonEntity:
          Name:
            NameFull: Serrano, P.
      – PersonEntity:
          Name:
            NameFull: Domenech, G.
      – PersonEntity:
          Name:
            NameFull: Torres, F.
      – PersonEntity:
          Name:
            NameFull: Donaire, A.
      – PersonEntity:
          Name:
            NameFull: Carreño, M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 00016314
          Numbering:
            – Type: volume
              Value: 138
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Acta Neurologica Scandinavica
              Type: main
ResultId 1